Literature DB >> 8738541

Lipoprotein abnormalities in chronic renal failure and dialysis patients.

G Monzani1, F Bergesio, R Ciuti, A Rosati, V Frizzi, A Serruto, D Vitali, A Benucci, P L Tosi, S Bandini, M Salvadori.   

Abstract

Lipoprotein abnormalities are common in patients with chronic renal failure (CRF) on either dialysis or conservative therapy. In order to investigate the changes in lipid and apolipoprotein pattern from early CRF to dialysis treatment, plasma lipids with apoproteins AI, B, E, CII, CIII, CII/CIII ratio, E/CIII ratio, parathyroid hormone (PTH) and insulin levels were examined in 72 patients with different degrees of CRF and 31 patients on hemodialysis (HD), and compared the values of 28 controls. A significant decrease in the Apo CII/CIII ratio was the earliest lipoprotein abnormality to occur in CRF. Hypertriglyceridemia (HTG) with reduced high-density lipoprotein cholesterol levels, increased Apo CIII and decreased Apo E/Apo CIII ratio only occurred in more advanced renal failure (creatinine clearance < 31 ml/min). HD patients showed a general worsening of the lipoprotein profile with elevated Apo E levels and indirect evidence of remnant accumulation. While PTH did not have any significant influence on lipoprotein pattern, increased insulin levels during HD might partly account for the HTG of these patients. Our results point to elevated Apo CIII, reduced Apo CII/Apo CIII and Apo E/ Apo CIII ratios as typical features of uremic hyperlipidemia and show that a defective triglyceride removal is the major pathogenetic mechanism of uremic HTG. HD treatment seems generally to worsen the lipid and apolipoprotein pattern observed in the predialytic stage of CRF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738541     DOI: 10.1159/000170270

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  3 in total

Review 1.  Lipoprotein metabolism in chronic renal insufficiency.

Authors:  Jeffrey M Saland; Henry N Ginsberg
Journal:  Pediatr Nephrol       Date:  2007-03-28       Impact factor: 3.714

2.  Physical activity and blood lipids and lipoproteins in dialysis patients.

Authors:  Hiroyuki Imamura; Keiko Mizuuchi; Reika Oshikata
Journal:  Int J Nephrol       Date:  2012-09-18

Review 3.  Slowing the progression of adult chronic kidney disease: therapeutic advances.

Authors:  Maarten W Taal
Journal:  Drugs       Date:  2004       Impact factor: 11.431

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.